Ambaye R Y, Indap M A, Naik S D
Cancer Research Institute, Tata Memorial Centre, Bombay, India.
J Cancer Res Clin Oncol. 1989;115(4):379-82. doi: 10.1007/BF00400966.
(R,S)3-(N,N-[bis-(2-chloroethyl)]-amino)-1-(2'-methoxyphenyl)- pyrrolidine-2,5-dione hydrochloride (I) has shown antitumor activity against P388 and L1210 leukaemias and Sarcoma 180 (ascites). The effect of (I), when co-administered with anticancer drugs, was studied in these murine tumours. Although co-administration of (I) with methotrexate showed a significant increase of the activity against P388 and L1210 leukaemias and Sarcoma 180 (ascites), co-administration of (I) with 5-fluorouracil, mitomycin C, adriamycin or vincristine did not exhibit any enhancing, synergistic or additive effect in the activity of these drugs.
（R，S）-3-（N，N-二（2-氯乙基）氨基）-1-（2'-甲氧基苯基）吡咯烷-2,5-二酮盐酸盐（I）已显示出对P388和L1210白血病以及肉瘤180（腹水型）具有抗肿瘤活性。在这些小鼠肿瘤中研究了（I）与抗癌药物联合给药时的效果。尽管（I）与甲氨蝶呤联合给药显示出对P388和L1210白血病以及肉瘤180（腹水型）的活性显著增加，但（I）与5-氟尿嘧啶、丝裂霉素C、阿霉素或长春新碱联合给药并未在这些药物的活性中表现出任何增强、协同或相加作用。
